ketamine therapy partner for PROVIDERS

Our Promise

At Corridor Ketamine we believe that teamwork is an essential part of providing the best possible healthcare experience for patients–and that starts by working collaboratively with you, their provider.

We recognize that we are not a patient’s primary care or mental health provider, but believe that what we do can work in tandem with their management plan. Our goal for those who seek our services is to be a place where they can receive safe, closely-monitored treatments that are in line with the current available published evidence

ketamine therapy partner for PROVIDERS

Our Promise

At Corridor Ketamine we believe that teamwork is an essential part of providing the best possible healthcare experience for patients–and that starts by working collaboratively with you, their provider.

We recognize that we are not a patient’s primary care or mental health provider, but believe that what we do can work in tandem with their management plan. Our goal for those who seek our services is to be a place where they can receive safe, closely-monitored treatments that are in line with the current available published evidence.

Monitoring

Research continues to prove that ketamine can be an effective part of a patient’s mental health plan, but like most things, it is not zero risk. Hemodynamic changes including increased blood pressure and heart rate are possible side effects, and in higher dosages, even airway events can present. As CRNAs and ARNPs, we are equipped to handle all monitoring and take appropriate action if the need arises.

CRNAs are:

The predominant providers of anesthesia in Iowa. They are the sole anesthesia providers in 88 out of 117 hospitals in the state.
Trusted professionals with proven safety outcomes.
Accustomed to close monitoring of patients throughout treatments.
Exceptionally familiar with ketamine administration.
Airway and hemodynamic management experts.

It's on these grounds that we feel our team of ARNPs are capable of serving as fantastic teammates, able to safely administer ketamine in the clinic setting for patients suffering from TRD.

What to Expect

We want to highlight our commitment to measurement-based care. We are able to track depression scores in a visual manner and generate charts that can aid in more clearly recognizing treatment progress.

Our electronic medical record platform, Osmind, allows for encrypted, HIPPA complaint correspondence with providers. This enables us to send updates on a patient’s progression throughout the induction phase of treatment and moving forward into the maintenance phase. We respect that you have been managing the treatment course for these patients and we will strive to remain fully transparent while your patients are under our care.

What To Expect Page

What to Expect

We want to highlight our commitment to measurement-based care. We are able to track depression scores in a visual manner and generate charts that can aid in more clearly recognizing treatment progress.

Our electronic medical record platform, Osmind, allows for encrypted, HIPAA compliant correspondence with providers. This enables us to send updates on a patient’s progression throughout the induction phase of treatment and moving forward into the maintenance phase. We respect that you have been managing the treatment course for these patients and we will strive to remain fully transparent while your patients are under our care.

What To Expect Page

Forms

REFERRAL FORM (DOC)

REFERRAL FORM (PDF)

Ketamine RESOURCES

Dold M, Bartova L, Kasper S: Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment. Int J Neuropsychopharmacol 2020; 23:440–445

Wilkinson ST, Toprak M, Turner MS, et al: A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry 2017; 174:695–696

Office of the Commissioner: FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. US Food and Drug Administration, 2019
https://www.fda.gov/news- events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available- only-certified

McIntyre RS, Carvalho IP, Lui LMW, et al: The effect of intravenous, intranasal, and oral ketamine/esketamine in mood disorders: a meta-analysis. J Affect Disord 2020; 276:576–584

Papakostas GI, Salloum NC, Hock RS, et al: Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry 2020; 81:19r12889

Andrade C: Ketamine for depression, 5: potential pharmacokinetic and pharmacodynamic drug interactions. J Clin Psychiatry 2017; 78:e858–e861

Sanacora G, Frye MA, McDonald W, et al: A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017; 74:399–405

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019 Jun 1;176(6):428-438

Bahji A, Vazquez GH, Zarate CA: Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021; 278:542–555 double-blind active-controlled study. Am J Psychiatry 2019; 176:428–438

ketamine therapy partner for PROVIDERS

Our Promise

ketamine therapy partner for PROVIDERS

Our Promise

Monitoring

What to Expect

We want to highlight our commitment to measurement-based care. We are able to track depression scores in a visual manner and generate charts that can aid in more clearly recognizing treatment progress.

What to Expect

We want to highlight our commitment to measurement-based care. We are able to track depression scores in a visual manner and generate charts that can aid in more clearly recognizing treatment progress.

Forms

Ketamine RESOURCES

Contact Us

Links

For PRoviders

Get Started

HiPPA Notice

Connect